雷公藤多苷/雷公藤片治疗类风湿关节炎的临床实践指南 2021

2021-01-14 Front Pharmacol . 2021 Jan 14;11:608703. doi: 10.3389/fphar.2020.608703

雷公藤（TwHF）是抗风湿性关节炎（RA）最常用和最有效的中药之一。雷公藤多甙片（TGT）和雷公藤多甙片（TWT）都是代表TwHF的代表性药物，已被纳入2019版《国家基本医疗保险，伤害保险和生育保险

中文标题：

英文标题：

Clinical Practice Guideline for Tripterygium Glycosides/ Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis

发布机构：

发布日期：

2021-01-14

简要介绍：

雷公藤（TwHF）是抗风湿性关节炎（RA）最常用和最有效的中药之一。雷公藤多甙片（TGT）和雷公藤多甙片（TWT）都是代表TwHF的代表性药物，已被纳入2019版《国家基本医疗保险，伤害保险和生育保险的医学目录》。但是，在治疗RA的过程中，患者之间的TGT / TWT反应通常存在个体差异，这意味着两种药物的临床应用可能未标准化，从而导致治疗无效和产生副作用的风险。越来越多的证据表明，TwHF的生物活性成分可能经常具有毒性，可能不会详细描述TGT和TWT的包装说明书，并且两种药物的治疗范围很窄。因此，迫切需要为TGT和TWT治疗RA制定标准化的临床实践指南。在本研究中，邀请了风湿病研究领域的一组中西医临床专家，药剂师和循证医学方法学家来选择临床问题，以确定证据水平和建议的强度，并制定建议和良好实践要点。该指南是根据临床研究证据和专家经验（循证，共识，经验补充）而形成的。由临床证据支持的临床问题可以形成建议，而没有临床证据的临床问题可以形成专家的建议。本指南中的建议和专家建议都系统地，全面地总结了TGT和TWT对RA的临床适应症，用法，剂量，联合用药和安全性，可在两种TwHF的临床应用中提供专业指导代理。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=efc331c00205a5d3, title=雷公藤多苷/雷公藤片治疗类风湿关节炎的临床实践指南 2021, enTitle=Clinical Practice Guideline for Tripterygium Glycosides/ Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis, guiderFrom=Front Pharmacol . 2021 Jan 14;11:608703. doi: 10.3389/fphar.2020.608703, authorId=0, author=, summary=雷公藤（TwHF）是抗风湿性关节炎（RA）最常用和最有效的中药之一。雷公藤多甙片（TGT）和雷公藤多甙片（TWT）都是代表TwHF的代表性药物，已被纳入2019版《国家基本医疗保险，伤害保险和生育保险, cover=https://img.medsci.cn/20211215/1639533528406_1614372.png, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Thu Jan 14 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=雷公藤（TwHF）是抗风湿性关节炎（RA）最常用和最有效的中药之一。雷公藤多甙片（TGT）和雷公藤多甙片（TWT）都是代表TwHF的代表性药物，已被纳入2019版《国家基本医疗保险，伤害保险和生育保险的医学目录》。但是，在治疗RA的过程中，患者之间的TGT / TWT反应通常存在个体差异，这意味着两种药物的临床应用可能未标准化，从而导致治疗无效和产生副作用的风险。越来越多的证据表明，TwHF的生物活性成分可能经常具有毒性，可能不会详细描述TGT和TWT的包装说明书，并且两种药物的治疗范围很窄。因此，迫切需要为TGT和TWT治疗RA制定标准化的临床实践指南。在本研究中，邀请了风湿病研究领域的一组中西医临床专家，药剂师和循证医学方法学家来选择临床问题，以确定证据水平和建议的强度，并制定建议和良好实践要点。该指南是根据临床研究证据和专家经验（循证，共识，经验补充）而形成的。由临床证据支持的临床问题可以形成建议，而没有临床证据的临床问题可以形成专家的建议。本指南中的建议和专家建议都系统地，全面地总结了TGT和TWT对RA的临床适应症，用法，剂量，联合用药和安全性，可在两种TwHF的临床应用中提供专业指导代理。, tagList=[TagDto(tagId=457, tagName=类风湿关节炎)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11720, appHits=455, showAppHits=0, pcHits=1398, showPcHits=11264, likes=3, shares=32, comments=41, approvalStatus=1, publishedTime=Sat Feb 13 17:14:36 CST 2021, publishedTimeString=2021-01-14, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Sat Feb 13 17:14:32 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 11:28:27 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=fphar-11-608703.pdf)])

fphar-11-608703.pdf

下载请点击：

评论区 (38)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2116425, encodeId=73052116425f0, content=很有意义的研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6638333665, createdName=ms5000001367546908, createdTime=Sat Feb 25 16:01:13 CST 2023, time=2023-02-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1213161, encodeId=4f47121316142, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:06:57 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212654, encodeId=1f98121265447, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:41:08 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085145, encodeId=9054108514580, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17326410074, createdName=bjcmsp, createdTime=Tue Dec 28 17:10:12 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081627, encodeId=4ee9108162e74, content=没有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85ed6399099, createdName=ms3000001232289033, createdTime=Sat Dec 18 21:30:15 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
2023-02-25 ms5000001367546908 来自重庆

很有意义的研究

34 0
[GetPortalCommentsPageByObjectIdResponse(id=2116425, encodeId=73052116425f0, content=很有意义的研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6638333665, createdName=ms5000001367546908, createdTime=Sat Feb 25 16:01:13 CST 2023, time=2023-02-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1213161, encodeId=4f47121316142, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:06:57 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212654, encodeId=1f98121265447, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:41:08 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085145, encodeId=9054108514580, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17326410074, createdName=bjcmsp, createdTime=Tue Dec 28 17:10:12 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081627, encodeId=4ee9108162e74, content=没有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85ed6399099, createdName=ms3000001232289033, createdTime=Sat Dec 18 21:30:15 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
2022-04-21 135434d0m28暂无昵称

谢谢分享

43 0
[GetPortalCommentsPageByObjectIdResponse(id=2116425, encodeId=73052116425f0, content=很有意义的研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6638333665, createdName=ms5000001367546908, createdTime=Sat Feb 25 16:01:13 CST 2023, time=2023-02-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1213161, encodeId=4f47121316142, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:06:57 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212654, encodeId=1f98121265447, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:41:08 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085145, encodeId=9054108514580, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17326410074, createdName=bjcmsp, createdTime=Tue Dec 28 17:10:12 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081627, encodeId=4ee9108162e74, content=没有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85ed6399099, createdName=ms3000001232289033, createdTime=Sat Dec 18 21:30:15 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
2022-04-19 qqnded

感谢分享

49 0
[GetPortalCommentsPageByObjectIdResponse(id=2116425, encodeId=73052116425f0, content=很有意义的研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6638333665, createdName=ms5000001367546908, createdTime=Sat Feb 25 16:01:13 CST 2023, time=2023-02-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1213161, encodeId=4f47121316142, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:06:57 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212654, encodeId=1f98121265447, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:41:08 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085145, encodeId=9054108514580, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17326410074, createdName=bjcmsp, createdTime=Tue Dec 28 17:10:12 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081627, encodeId=4ee9108162e74, content=没有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85ed6399099, createdName=ms3000001232289033, createdTime=Sat Dec 18 21:30:15 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
2021-12-28 bjcmsp

下载学习

0 0
[GetPortalCommentsPageByObjectIdResponse(id=2116425, encodeId=73052116425f0, content=很有意义的研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6638333665, createdName=ms5000001367546908, createdTime=Sat Feb 25 16:01:13 CST 2023, time=2023-02-25, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1213161, encodeId=4f47121316142, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:06:57 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212654, encodeId=1f98121265447, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:41:08 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085145, encodeId=9054108514580, content=下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17326410074, createdName=bjcmsp, createdTime=Tue Dec 28 17:10:12 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081627, encodeId=4ee9108162e74, content=没有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85ed6399099, createdName=ms3000001232289033, createdTime=Sat Dec 18 21:30:15 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
2021-12-18 ms3000001232289033

没有中文版吗

47 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

风湿免疫科指南

雷公藤多苷/雷公藤片治疗类风湿关节炎的临床实践指南 2021

相关指南

科室

工具

服务